en · de · es · pt
methods-notes.peptides4800.com › News › Tb-500 Background And Identity — What the Evidence Shows

Tb-500 Background And Identity — What the Evidence Shows

By Editorial Desk · published 2025-12-14 · last reviewed 2026-01-23 · News

If you have been reading about Research peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-01-23. Numbers and descriptions here follow the published literature rather than marketing material.

TB-500 Background and Identity

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

Identity and Research Background

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Tb-500 at a glance

PropertyValueNotes
AppearanceWhite to off-white lyophilized powderTypical form for short synthetic peptides
Solubility classFreely soluble in water and aqueous bufferDissolution aided by gentle mixing, not vigorous shaking
Typical storage temperature−20 °C, desiccated−80 °C used for long-term holding
Common analytical methodReverse-phase HPLC with UV detection near 214 nmIdentity confirmed separately by mass spectrometry
Common synonymsThymosin beta-4 fragment; TB4 fragmentNaming varies between suppliers and publications

Thymosin Beta-4 Fragment Background

Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.

TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.

Related pages on this site

Identity And Naming Background

Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.

TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.

Storage, Handling, and Analytical Checks

Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.

The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.

Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.

Background from the literature

=== People in Kazuko's life === Toma Ikuta as Masaya Hotta, a yakuza figure who becomes Kazuko's lover and business partner. Tetta Sugimoto as Sojiro Takiguchi, an underworld figure who exploits Kazuko after her financial downfall. Eita Okuno as Hajime Ochiai (episode 1), a bar owner who hires Kazuko as a hostess. Kentaro Tamura as Marohiko Mita (episodes 2–3), Kazuko's husband from a wealthy traditional family. Ayumu Nakajima as Yutaka Sudo (episodes 3–4), a real estate agent who becomes romantically involved with Kazuko. Renji Ishibashi as Masataka Yasunaga (episodes 8–9), a respected scholar of Yangmingism who later becomes connected to Kazuko.

MRI with diffusion weighted inversion (DWI) and fluid-attenuated inversion recovery (FLAIR) shows a high signal intensity in certain parts of the cortex (a cortical ribboning appearance), the basal ganglia, and the thalami. The most common presenting patterns are simultaneous involvement of the cortex and striatum (60% of cases), cortical involvement without the striatum (30%), thalamus (21%), cerebellum (8%) and striatum without cortical involvement (7%). In populations with a rapidly progressive dementia (early in the disease process), MRI has a sensitivity of 91% and specificity of 97% for diagnosing CJD. The MRI changes characteristic of CJD may also be seen in the immediate aftermath (hours after the event) of autoimmune encephalitis or focal seizures. In recent years, studies have shown that the tumour marker neuron-specific enolase (NSE) is often elevated in CJD cases; however, its diagnostic utility is seen primarily when combined with a test for the 14-3-3 protein. As of 2010, screening tests to identify infected asymptomatic individuals, such as blood donors, are not yet available, though methods have been proposed and evaluated.

== Processing/Synthesis == Peptide synthesis can be easily conducted by the established method of solid-phase chemistry in gram or kilogram quantities. The d-isomer conformation can be used for peptide synthesis. Nanostructures can be made by dissolving dipeptides in 1,1,1,3,3,3-hexafluoro-2-propanol at 100 mg/ml and then diluting it with water for a concentration of less than 2 mg/ml. Multiwall nanotubes with diameters of 80–300 nm, made of dipeptides from the diphenylalanine motif of Alzheimer's β-amyloid peptide are made by this method. If a thiol is introduced into the diphenylalanine then nano-spheres can be formed instead; nanospheres with diameters of 10–100 nm can also be made this way, from a diphenylglycine peptide.

== Cellular functions == Proteins are the chief actors within the cell, said to be carrying out the duties specified by the information encoded in genes. With the exception of certain types of RNA, most other biological molecules are relatively inert elements upon which proteins act. Proteins make up half the dry weight of an Escherichia coli cell, whereas other macromolecules such as DNA and RNA make up only 3% and 20%, respectively. The set of proteins expressed in a particular cell or cell type is known as its proteome.

Sources: en.wikipedia.org

Further detail

== Plot == For generations, vampires and Lycans, an ancient species of werewolf, have secretly waged war. The vampires gain the upper hand when Lycan leader Lucian seemingly dies at the hands of vampire Kraven, who becomes the second-in-command to the vampires' leading elders. Selene, a member of an elite group of vampire assassins known as "Death Dealers", continues to pursue the extermination of the Lycans despite other vampires no longer perceiving them as a threat. After a clash with the Lycans, Selene discovers that they are after Michael Corvin, a seemingly ordinary resident doctor. Disregarding Kraven’s insistence to ignore the situation, Selene privately investigates Michael. The pair is pursued by a group of Lycans led by Lucian, who manages to bite Michael during their escape. Since Kraven was the only witness to Lucian's supposed death, Selene begins to suspect that he lied about the death and may be working with the Lycans. Selene prematurely awakens Viktor, a hibernating elder vampire and leaves to hide Michael in a safe house. Selene binds Michael, anticipating the Lycans' bite will transform him into a werewolf when the full moon rises. As the two of them bond, she gradually tells him more about her past, revealing that Viktor adopted her and turned her into a vampire after her family's death at the hands of Lycans, leading her to start a vengeful campaign against them, and that Michael's hallucinations are memories that Lucian passed down to him. Selene returns to her coven's mansion.

=== Gene therapy === Viral gene therapy involves artificially manipulating a virus to include a desirable piece of genetic material. Viral gene therapies using engineered plant viruses have been proposed to enhance crop performance and promote sustainable production.

The military occupation of Czechoslovakia by Nazi Germany began with the German annexation of the Sudetenland in 1938, continued with the creation of the Protectorate of Bohemia and Moravia, and by the end of 1944 extended to all parts of Czechoslovakia. Following the Anschluss of Austria in March 1938 and the Munich Agreement in September of that same year, Adolf Hitler annexed the Sudetenland from Czechoslovakia on 1 October, giving Germany control of the extensive Czechoslovak border fortifications in this area. The incorporation of the Sudetenland into Germany left the rest of Czechoslovakia ("Rest-Tschechei" ) with a largely indefensible northwestern border. Also a Polish-majority borderland region of Trans-Olza which was annexed by Czechoslovakia in 1919, was occupied and annexed by Poland following the two-decade long territorial dispute. Finally the First Vienna Award gave to Hungary the southern territories of Slovakia and Carpathian Ruthenia, mostly inhabited by Hungarians. On 14 March 1939, the Slovak parliament voted unanimously to establish an independent Slovak state and German troops preemptively marched into Ostrava to prevent the Poles from occupying the region. The following day, during a visit to Berlin, the Czechoslovak president Emil Hácha was coerced into signing away his country's independence as Hungary annexed the remainder of Carpathian Ruthenia. On 16 March, Hitler proclaimed the Protectorate of Bohemia and Moravia from Prague Castle, leaving Hácha as the nominal, but almost powerless, State President.

The term poison is often used colloquially to describe any harmful substance, especially corrosive substances, carcinogens, mutagens, teratogens, and harmful pollutants. In everyday language, it is sometimes used to exaggerate the perceived danger of certain chemicals. The 16th-century physician Paracelsus (1493–1541), regarded as the father of toxicology, famously stated: "Everything is poison, there is poison in everything. Only the dose makes a thing not a poison." (See: LD50). The term is also used in a figurative sense—for example: "His brother's presence poisoned the atmosphere at the party." In contrast, legal definitions of "poison" tend to be narrower. Some substances that are not legally required to carry a "poison" label may still cause medical conditions associated with poisoning. Some poisons are also classified as toxins, which are toxic substances produced by living organisms. Examples include bacterial proteins responsible for conditions such as tetanus and botulism. While a distinction exists between "poison" and "toxin", the terms are often used interchangeably, even in scientific contexts. Related adjectives include toxic and poisonous, which are generally considered synonymous. Poisonous substances introduced into the body by sting or bite are known as venoms. In everyday usage, a poisonous organism is one that causes harm when ingested or touched, while a venomous organism uses venom actively to incapacitate prey or deter predators. Although rare, some organisms may be both poisonous and venomous.

The price of real estate in Moscow continues to increase. The expected price averages $4,000 per square meter (11 sq ft) near the perimeter of the city or $6,500–8,000 per square meter in a prestigious district. The price sometimes exceeds $40,000 per square meter for a flat. Renting costs about $1,200 per month for a one-bedroom apartment and about $1,000 per month for a studio in the city center. A typical one-bedroom apartment in Moscow is about 30 square meters (320 square feet) in area; a typical two-bedroom apartment is 45 square meters (480 square feet); and a typical three-bedroom apartment is 70 square meters (750 square feet). Many residents cannot move out of their apartments, especially if a family lives in a two-room apartment originally granted by the state during the Soviet era. Some city residents have attempted to cope with the cost of living by renting out their apartments while staying in dachas (country houses) outside the city. In 2006, Mercer Human Resources Consulting named Moscow the world's most expensive city for expatriate employees, ahead of recurring winner Tokyo, because of the stable Russian ruble as well as increasing housing prices. Moscow also ranked first in the 2007 edition and 2008 edition of the survey. However, in 2009, Tokyo overtook Moscow, which came in third after Osaka. In 2014, according to Forbes magazine, Moscow was ranked the world's ninth most expensive city. This magazine ranked Moscow the second most expensive city the previous year.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.

Is TB-500 identical to thymosin beta-4?

Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.

Is TB-500 an approved medicine?

No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.

Network